Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

240 cirrhosis patients studied to uncover hidden clot risks

NCT ID NCT07560202

Knowledge-focused Sponsor: Elham Ahmed Hassan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 240 adults with liver cirrhosis to learn more about a common complication called portal vein thrombosis (a blood clot in the liver's main vein). Researchers will use ultrasound and CT scans to find clots and track their patterns. The goal is to identify which patients are most at risk, helping doctors better manage and prevent this serious condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

240 people

The number who actually took part.

Started

Jun 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with liver cirrhosis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with liver cirrhosis Exclusion Criteria: * Patients with non-hepatic hemostatic disorders, active bacterial sepsis, renal dysfunction, peripheral or hepatic venous thrombosis, recent splenectomy, liver transplantation, antiplatelet or anticoagulant therapy or contraceptive pills were excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis Portal vein thrombosis

Contacts and locations

Locations

  • Assiut University Hospital

    Asyut, 71515, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.